These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 1534089)
1. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089 [TBL] [Abstract][Full Text] [Related]
2. Goserelin (Zoladex) in the treatment of fibroids. West CP; Lumsden MA; Baird DT Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():27-30. PubMed ID: 1532507 [No Abstract] [Full Text] [Related]
3. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Maheux R; Lemay A; Blanchet P; Friede J; Pratt X Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823 [TBL] [Abstract][Full Text] [Related]
5. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. West CP; Lumsden MA; Lawson S; Williamson J; Baird DT Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863 [TBL] [Abstract][Full Text] [Related]
6. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids. Lumsden MA; West CP; Hillier H; Baird DT Fertil Steril; 1989 Dec; 52(6):924-9. PubMed ID: 2531684 [TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921 [TBL] [Abstract][Full Text] [Related]
8. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092 [TBL] [Abstract][Full Text] [Related]
9. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach. Lemay A; Faure N J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711 [TBL] [Abstract][Full Text] [Related]
10. [Intrauterine pregnancy with uterine myoma after downregulation with GnRH analogs]. Naether O; Diedrich K Geburtshilfe Frauenheilkd; 1992 Feb; 52(2):121-2. PubMed ID: 1314757 [TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Caird LE; West CP; Lumsden MA; Hannan WJ; Gow SM Hum Reprod; 1997 Mar; 12(3):436-40. PubMed ID: 9130735 [TBL] [Abstract][Full Text] [Related]
12. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis. Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047 [TBL] [Abstract][Full Text] [Related]
13. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Robertson JF; Walker KJ; Nicholson RI; Blamey RW Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556 [TBL] [Abstract][Full Text] [Related]
14. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Thomas EJ Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983 [TBL] [Abstract][Full Text] [Related]
15. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630). Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844 [TBL] [Abstract][Full Text] [Related]
16. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids. Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144 [TBL] [Abstract][Full Text] [Related]
17. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870 [TBL] [Abstract][Full Text] [Related]
18. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. West CP; Baird DT Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405 [TBL] [Abstract][Full Text] [Related]
19. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex. Holdaway IM; Parr CE; France J Aust N Z J Obstet Gynaecol; 1991 May; 31(2):164-5. PubMed ID: 1834050 [TBL] [Abstract][Full Text] [Related]
20. Use of GnRH depot analogue in the treatment of uterine fibroids. Auber G; Ricci G; Barciulli F; Pregazzi R; D'Ancona RL; Toffoletti FG Acta Eur Fertil; 1990; 21(4):185-9. PubMed ID: 2150737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]